BeStock  
Stocks › Biotechnology › RIGL

Rigel Pharmaceuticals RIGL

US equityMarket cap rank #3311Biotechnology
$47.99 +$1.88 (+4.08%)
Pre-market · Oct 8, 8:40 am ET · After hours $47.00 -2.06%
Open$45.64
Prev close$46.11
Day range$45.22 – $48.15
Volume232.6K
Market cap$896.45M
P/E (TTM)2.8
Dividend yield–

Valuation

Multiples measured against the stock's own five-year history

Price / earnings2.8x
CheapRich

Above its usual level · 73rd percentile, 5-year average -0.2x

#124 of 2973 stocks by PE (1 = cheapest)

Price / book2.1x
CheapRich

Above its usual level · 63rd percentile, 5-year average 0.6x

#3039 of 5317 stocks by PB (1 = cheapest)

Price / sales3.2x
CheapRich

Near the top of its 5-year range · 90th percentile, 5-year average 2.2x

#3224 of 5146 stocks by PS (1 = cheapest)

P/E over five years

-83x-18x47x112xOct '21Apr '24Oct '26

Dashed line is the 5-year average; the shaded band is one standard deviation either side.

Morningstar fair value estimate

Fair value$56.99
Price vs. fair value-15.8%Trading below the estimate
Star rating★★★★☆
Economic moatNone
UncertaintyHigh
MultipleCurrentForward5y averagePercentile vs. own historyIndustry rank
PB 2.11 – 0.59 63% (pricier than usual) #3039 of 5317 (1 = cheapest)
PE 2.84 13.93 -0.16 73% (pricier than usual) #124 of 2973 (1 = cheapest)
PS 3.24 2.69 2.24 90% (pricier than usual) #3224 of 5146 (1 = cheapest)

Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.

Morningstar view

Star rating★★★★
Fair value estimate$56.99
Economic moatNone
UncertaintyHigh

Discussion

No comments yet — be the first to weigh in on RIGL.

Leave a comment

Scroll to Top